Notably, S1P-modulators showed the highest neoplasia rates (fingolimod 31/2129, 1.4%, siponimod 3/200, 1.5%), whereby basal cell carcinomas accounted for the largest proportion (fingolimod 13/31, 42%; siponimod 1/3, 33.3%). This evidence concerns the gene MBTPS1 and neoplasm.